JPH08510719A - 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用 - Google Patents

有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用

Info

Publication number
JPH08510719A
JPH08510719A JP6517615A JP51761594A JPH08510719A JP H08510719 A JPH08510719 A JP H08510719A JP 6517615 A JP6517615 A JP 6517615A JP 51761594 A JP51761594 A JP 51761594A JP H08510719 A JPH08510719 A JP H08510719A
Authority
JP
Japan
Prior art keywords
cells
mab
lps
induced
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6517615A
Other languages
English (en)
Japanese (ja)
Inventor
ゴルドマン，ミシェル
ヴェル，ティエリー
アブラモウィツ，ダニエル
ブリュインス，カトリーヌ
カペル，パウル
デルヴォ，アンヌ
ドンキエール，ヴァンサン
ジェラード，カトリーヌ
マルシャン，アルノー
プラディエール，オリヴィエール
シャンデネ，リリアン
ウィレム，ファビエヌ
Original Assignee
ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル filed Critical ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル
Publication of JPH08510719A publication Critical patent/JPH08510719A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP6517615A 1993-02-01 1994-02-01 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用 Pending JPH08510719A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93400242.9 1993-02-01
EP93400242 1993-02-01
PCT/EP1994/000283 WO1994017773A2 (fr) 1993-02-01 1994-02-01 Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10

Publications (1)

Publication Number Publication Date
JPH08510719A true JPH08510719A (ja) 1996-11-12

Family

ID=8214672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6517615A Pending JPH08510719A (ja) 1993-02-01 1994-02-01 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用

Country Status (5)

Country Link
EP (1) EP0681589A1 (fr)
JP (1) JPH08510719A (fr)
AU (1) AU6000894A (fr)
CA (1) CA2155109A1 (fr)
WO (1) WO1994017773A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511510A (ja) * 2002-11-29 2006-04-06 ロンカルオロ，マリア，グラジア 免疫疾患治療用ラパマイシン及びｉｌ−１０
JP2016519108A (ja) * 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
JP2018104341A (ja) * 2016-12-27 2018-07-05 国立研究開発法人国立循環器病研究センター リポソーム組成物及び炎症性疾患用治療剤

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756871A1 (fr) * 1995-08-01 1997-02-05 Institut Pasteur Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
CA2228379A1 (fr) * 1995-08-09 1997-02-20 Schering Corporation Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
WO1998026066A1 (fr) * 1996-12-09 1998-06-18 Ariad Gene Therapeutics, Inc. Expression de proteines pour traiter l'asthme via l'activation, par ligand mediateur, de leurs genes de codage
EP1284747A2 (fr) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
RU2538613C2 (ru) * 2012-10-11 2015-01-10 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук Интерлейкин-10, его применение и композиция на его основе для лечения нейродегенеративных процессов в мозге
EP3010527B1 (fr) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
WO2016060996A2 (fr) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Compositions d'interleukine-15 et leurs utilisations
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633034B2 (en) * 1988-11-03 1993-01-21 Schering Corporation Method of preventing or reducing eosinophilia
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
EP0600970B1 (fr) * 1991-08-06 1999-12-08 Schering Corporation Utilisation d'analogues ou d'antagonistes de l'interleukine-10 pour traiter la toxicite induite par l'endotoxine ou un superantigene
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
WO1993018783A1 (fr) * 1992-03-20 1993-09-30 Schering Corporation Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1
RU2120802C1 (ru) * 1992-08-20 1998-10-27 Шеринг Корпорейшн Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511510A (ja) * 2002-11-29 2006-04-06 ロンカルオロ，マリア，グラジア 免疫疾患治療用ラパマイシン及びｉｌ−１０
JP2016519108A (ja) * 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
JP2018104341A (ja) * 2016-12-27 2018-07-05 国立研究開発法人国立循環器病研究センター リポソーム組成物及び炎症性疾患用治療剤

Also Published As

Publication number Publication date
WO1994017773A3 (fr) 1994-12-22
WO1994017773A2 (fr) 1994-08-18
AU6000894A (en) 1994-08-29
CA2155109A1 (fr) 1994-08-18
EP0681589A1 (fr) 1995-11-15

Similar Documents

Publication Publication Date Title
JPH08510719A (ja) 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
Egholm et al. The regulatory effects of interleukin-4 receptor signaling on neutrophils in type 2 immune responses
Salomon et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2–deficient NOD mice
KR0170037B1 (ko) 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
JP6758259B2 (ja) Ｔ細胞調節方法
Erhardt et al. IL‐10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A–induced liver injury in mice
Kumar et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice
Jönsson et al. Mast cells and company
KR100602940B1 (ko) 염증성 장질환 치료제
KR100609444B1 (ko) 이식편 거절반응 억제제
Haspot et al. Anti‐CD28 Antibody‐Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR− Class II− B7+ Regulatory Cells
EP2040730B1 (fr) Modulation du nkg2d chez des patients infectes par hbv
Karimi et al. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT
Kim et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7–1 in initiation versus progression of graft arteriosclerosis
US20120269806A1 (en) Methods of inducing tolerance
Wang et al. Lymphocytic subsets play distinct roles in heart diseases
Ngo Nyekel et al. Mast cell degranulation exacerbates skin rejection by enhancing neutrophil recruitment
Furukawa et al. Association of B7-1 co-stimulation with the development of graft arterial disease: studies using mice lacking B7-1, B7-2, or B7-1/B7-2
JPH11506915A (ja) Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン
Wang et al. Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance
Kumamoto et al. Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice
Bergese et al. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression
Sido et al. Modulation of the CD2 receptor and not disruption of the CD2/CD48 interaction is the principal action of CD2-mediated immunosuppression in the rat
Koch et al. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier
SHENG-TANNER et al. Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation: role of class I and class II major histocompatibility complex